Erik C. Emerson
Chief Executive Officer, Director · Apimeds Pharmaceuticals US, Inc.
Individual
- 2025
- Oct 15, 2025
- 1
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Erik C. Emerson's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Hellman & Friedman Capital Partners X (Parallel), L.P. - $2.65B in MDLN purchases and sales in the last 12 months
- BX Mozart ML-2 Holdco L.P. - $2.35B in MDLN purchases and sales in the last 12 months
- BCP 8 Holdings Mozart Manager L.L.C. - $2.35B in MDLN purchases and sales in the last 12 months
- LILLY ENDOWMENT INC - $2.23B in LLY purchases and sales in the last 12 months
- KKR Phoenix Aggregator L.P. - $2.09B in BTSG purchases and sales in the last 12 months
- KKR Group Partnership L.P. - $2.09B in BTSG purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Erik C. Emerson?
Erik C. Emerson is a corporate insider, tracked as Chief Executive Officer, Director of Apimeds Pharmaceuticals US, Inc. (APUS). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Erik C. Emerson last file a Form 4?
The only primary Form 4 on record is dated 15 October 2025.